KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $1.16.

  • Gilead Sciences' Debt to Equity fell 841.05% to $1.16 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.16, marking a year-over-year decrease of 841.05%. This contributed to the annual value of $1.38 for FY2024, which is 2580.75% up from last year.
  • Gilead Sciences' Debt to Equity amounted to $1.16 in Q3 2025, which was down 841.05% from $1.27 recorded in Q2 2025.
  • Gilead Sciences' 5-year Debt to Equity high stood at $1.59 for Q1 2021, and its period low was $1.1 during Q4 2023.
  • Its 5-year average for Debt to Equity is $1.28, with a median of $1.27 in 2025.
  • Data for Gilead Sciences' Debt to Equity shows a peak YoY increase of 4640.87% (in 2021) and a maximum YoY decrease of 2646.33% (in 2021) over the last 5 years.
  • Gilead Sciences' Debt to Equity (Quarter) stood at $1.27 in 2021, then dropped by 6.13% to $1.19 in 2022, then fell by 7.67% to $1.1 in 2023, then grew by 25.81% to $1.38 in 2024, then dropped by 16.21% to $1.16 in 2025.
  • Its last three reported values are $1.16 in Q3 2025, $1.27 for Q2 2025, and $1.3 during Q1 2025.